Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema.

Trial Profile

Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Diabetic macular oedema; Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms IBERA-DME
  • Most Recent Events

    • 01 Sep 2013 Primary endpoint of central subfield macular thickness change from baseline to 48 week has been met, according to result published in the American Journal of Ophthalmology.
    • 10 Dec 2011 New trial record
    • 31 Aug 2011 Recruitment completed, according to result published in American Journal of Ophthalmology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top